# Tragara Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tragara-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Carlsbad, US
- Website: www.tragarapharma.com
- Total disclosed funding: $56M
- Latest round: Series B (Sep 3, 2013)
- Investors on record: 7

## About

Tragara Pharmaceuticals, Inc. focuses on the development and commercialization of innovative therapies for cancer treatment, aiming to enhance patient outcomes through advanced pharmaceutical solutions.Tragara Pharmaceuticals, Inc. is dedicated to creating therapies for oncology applications. Founded in 2007, the company is headquartered in Carlsbad, California, US. It has engaged in 7 funding deals, with its most recent deal occurring on November 15, 2016, when it raised USD 3.26 mn. The current CEO is Scott Megaffin, who has a history of leadership within the pharmaceutical sector.Tragarapharma.com operates within the domain marketplace, facilitating the buying and selling of internet domains. The company's core service is connecting domain sellers with potential buyers, thereby streamlining the transaction process for digital real estate. Customers include individual entrepreneurs, small businesses, and large corporations looking to establish or enhance their online presence through premium domain names. The platform is designed to assist in identifying valuable domain names that align with a client’s branding needs and market strategy. Tragarapharma.com primarily serves clients in North America and Europe, offering a widespread geographic reach that enables various end users to engage in domain transactions effectively.The revenue structure of Tragarapharma.com is predominantly based on transaction fees generated from domain sales facilitated through its platform. Each sale incurs a service charge, which constitutes the main revenue stream for the company. Transactions typically occur on a B2B basis, where businesses engage directly with the company to purchase or sell domains. Pricing models may vary based on the domain's perceived value, with higher prices for premium or trademarked domains. This structured approach ensures that both buyers and sellers receive a fair market rate for their domains, while the company benefits from a commission on completed sales, ensuring a sustainable revenue model.In November 2016, Tragara Pharmaceuticals, Inc. raised USD 3.26 mn in venture funding from unspecified investors. The company plans to utilize this funding to enhance its product offerings and expand its presence in new markets. Upcoming new products are being designed, and the company is targeting growth in North America and Europe, with a strategic focus on launching these initiatives within the next year.

## Funding rounds

- Series B, Sep 3, 2013, $11M — Domain Associates, Morgenthaler Ventures, MIC Capital, ProQuest Investments, RMI Partners
- Series A, Jan 28, 2010, $5M — Domain Associates, Morgenthaler Ventures, Oxford Bioscience Partners, ProQuest Investments, MC Capital
- Series A, Mar 6, 2007, $40M — Domain Associates, Morgenthaler Ventures, Oxford Bioscience Partners, MIC Capital, ProQuest Investments

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series B
- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series A, Series B
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series A
- MIC Capital — Series A, Series B
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series A, Series B
- MC Capital — Series A
- RMI Partners (https://capitalatlas.ai/funds/rmi-partners) — Series B